How to buy Aurinia Pharmaceuticals shares | US$15

Own your own AUPH stock in just a few minutes.

Posted

Fact checked

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

US$15
current price
US$0.12
change
0.806%
change %

How to buy stock in Aurinia Pharmaceuticals

  1. Compare share trading platforms. To buy shares in a US company from New Zealand you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, including your ID. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aurinia Pharmaceuticals. Find the share by name or ticker symbol: AUPH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aurinia Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of US$15, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Aurinia Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aurinia Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
  7. Price details for Aurinia Pharmaceuticals (AUPH)

    Open $15 Previous close $14.88
    High $15.33 Change $0.12
    Low $14.75 Change % 0.806%
    Close $15 Timestamp 1594666560
    Volume N/A GMT offset 0

    Aurinia Pharmaceuticals stock price

    Use our graph to track the performance of AUPH stocks over time.

    Compare share trading platforms

    Data indicated here is updated regularly
    Name Product Monthly fee Currency conversion fee Available markets
    Stake
    $0
    1% ($2 min)
    NASDAQ
    NYSE
    BATS
    Chicago Stock Exchange
    And more
    Sign up through Finder and use referral code "FINDERNZ" for a free stock. Trade 3,500 US listed stocks and ETFs through Stake with $0 brokerage.
    loading

    Compare up to 4 providers

    The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

    Aurinia Pharmaceuticals company summary

    Information last updated 2020-07-12.

    Aurinia Pharmaceuticals (AUPH) is a leading Biotechnology business based in the USA. Aurinia Pharmaceuticals (AUPH) is listed on the NASDAQ and employs 62 staff.

    Profile

    Industry Biotechnology Currency symbol $
    Code AUPH Country name USA
    Type Common Stock Country ISO US
    Name Aurinia Pharmaceuticals Inc ISIN US05156V1026
    Exchange NASDAQ CUSIP 05156V102
    Currency code USD Sector Healthcare
    Currency name US Dollar Full-time employees 62

    Detailed company information

    Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Go to site